VivoSeq
Psychiatry

Anxiety

129

Pipeline Programs↗

51

Active Trials↗

47

Companies Involved↗

Anxiety is a highly competitive landscape with 129 programs across 47 companies. The most active players are Azevan Pharmaceuticals, Nobilis Therapeutics Inc., Retrophin. 30 therapies are approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

61/100

Mech. Concentration

12/100

Completion Rate

87/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Azevan Pharmaceuticals

1 program

Phase 1N

Nobilis Therapeutics Inc.

1 program

Phase 1R

Retrophin

1 program

Phase 1L

Lykos Therapeutics

2 programs

Phase 2V

VistaGen Therapeutics, Inc.

1 program

Phase 2V

Vanda Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical39

Acamprosate

Forest Laboratories

Testosterone

Auxilium

Propofol

Fresenius Kabi Oncology Ltd.

Remimazolam

Acacia Pharma Ltd

Clonidine

Boehringer Ingelheim

Phase 112

Oxytocin

Retrophin

Nicotine

Pfizer

Endotoxin

University of California, Los Angeles

Niacin

AbbVie

Disulfiram

Teva

Phase 232

Paroxetine

Sebela Pharmaceuticals Development LLC

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Cannabidiol

Jazz Pharmaceuticals

Lidocaine

MEDRx USA, Inc.

Psilocybin

COMPASS Pathways

Phase 316

Duloxetine Hydrochloride

Eli Lilly

Melatonin

Neurim Pharmaceuticals Ltd.

Diazepam

Akero Therapeutics

Fentanyl

Cephalon

Venlafaxine

Wyeth-Lederle Vaccines

Approved30

Risperidone

Wim Janssens

Lorazepam

Bausch Health Americas, Inc.

Memantine

AbbVie

Gabapentin

Viatris Specialty LLC

Buspirone

Bristol-Myers Squibb

Analysis

Trial Status

239

clinical trials

Completed144 · 60%
Recruiting29 · 12%
Unknown status22 · 9%
Not yet recruiting19 · 8%
Terminated17 · 7%
Withdrawn4 · 2%
Other4 · 2%

Clinical Trials

Trial Activity

239 trials

Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety
Recruiting·—·N/A·NCT05683223·240 enrolled
SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety
Recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07174947·240 enrolled
Administration of Intranasal Midazolam for Anxiety in Palliative Care
Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT06330584·36 enrolled
Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients
Recruiting·TTianjin Medical University General Hospital·N/A·NCT06108830·400 enrolled
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
Recruiting·LLaureate Institute for Brain Research, Inc.·Phase 4·NCT06004115·165 enrolled
Anxiety During Abstinence in AUD
Recruiting·—·Phase 1·NCT06793488·60 enrolled
Clinical Study of Dexmedetomidine Administered Intranasally to Relieve Perioperative Anxiety and Depression in Patients With Colorectal Tumors
Recruiting·FFirst Affiliated Hospital of Chongqing Medical University·Phase 3·NCT06139926·126 enrolled
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
Recruiting·HHolland Bloorview Kids Rehabilitation Hospital·Phase 2·NCT06081348·130 enrolled
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Recruiting·Otsuka logoOtsuka·Phase 3·NCT06973577·308 enrolled
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
Recruiting·UUniversity of Cincinnati·Phase 4·NCT04245436·60 enrolled
Management of Preoperative Anxiety in Children: Could a Lollipop Be the Solution?
Recruiting·TTunis University·N/A·NCT06670846·63 enrolled
Cannabidiol Effects on Learning and Anxiety
Recruiting·UUniversity of Connecticut·Phase 1·NCT05283382·160 enrolled
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
Recruiting·UUniversity of Washington·Phase 2·NCT07336238·18 enrolled
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
Recruiting·UUniversity of Cincinnati·Phase 4·NCT04623099·132 enrolled
Affect of Duavive on Mood & Anxiety Symptoms
Recruiting·SSt. Joseph's Healthcare Hamilton·Phase 1·NCT04478305·30 enrolled
Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)